Robert A. Michael - Feb 25, 2022 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role
Vice Chairman
Signature
Steven L. Scrogham, attorney-in-fact for Robert A. Michael
Stock symbol
ABBV
Transactions as of
Feb 25, 2022
Transactions value $
-$11,517,375
Form type
4
Date filed
3/1/2022, 05:07 PM
Previous filing
Feb 22, 2022
Next filing
Feb 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABBV Common Stock, $0.01 par value Tax liability -$5.13M -34.3K -29.74% $149.54 81K Feb 25, 2022 Direct
transaction ABBV Common Stock, $0.01 par value Sale -$1.76M -11.9K -14.73% $147.41 69.1K Mar 1, 2022 Direct F1
transaction ABBV Common Stock, $0.01 par value Sale -$4M -26.9K -39.01% $148.49 42.1K Mar 1, 2022 Direct F2
transaction ABBV Common Stock, $0.01 par value Sale -$631K -4.24K -10.06% $149.06 37.9K Mar 1, 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.875 to $147.86 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.87 to $148.86 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.87 to $149.44 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

The sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).